Supernus Pharmaceuticals SUPN Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesFairValueDisclosure.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's total liabilities?
- Supernus Pharmaceuticals (SUPN) reported total liabilities of $206K in Q1 2026.
- How has Supernus Pharmaceuticals's total liabilities changed year-over-year?
- Supernus Pharmaceuticals's total liabilities decreased by 99.9% year-over-year, from $316.59M to $206K.
- What is the long-term trend for Supernus Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's total liabilities has grown at a -47.2% compound annual growth rate (CAGR), from $759.24M to $31.26M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.